Schwab Network 对 $MRK 的判断变化

频道资料 →频道引用的来源:BFA and JP Morgan、Baird、Bank of America、Barclays、Berenberg、Bernstein、Bernstein, with a Jefferies target cut noted、Bilal Little、Bird (analyst firm)、CEO、CEO Joe Dominguez、Caner、Citi、Citigroup、Citizens、Daiwa、Dan Deming and Michael Monahan、Dan Ies; Morgan Stanley、Dan Ives、Dan Ives and unnamed analysts、Deutsche Bank、Erit Research、Evercore ISI、Evercore ISI; Dan Ives、Goldman Sachs、JP Morgan Chase、JPMorgan、JPMorgan Chase、James Demerard of Wall Street Research、Jefferies、Jefferies, UBS and Citigroup、Jensen Huang; Dan Ives、KeyBank、Loop Capital、Mattie Natsson、Michael Saylor、Milius (analyst)、Morgan Stanley、Northrop、Oppenheimer、Oppenheimer, Freedom Broker、Oracle、PFA analysts、Quantum CEO、RBC、Reddit CEO、Rothschild Redburn、SK Hynix、Seth、Tim Bigham、Tim and KG、Truist、UBS、Wall Street Journal、Wedbush、Wells Fargo、analysts、the street共 2 条

Schwab Network 自 2026-09-09 起在 2 个视频里谈过 $MRK,最近一次(2026-10-15)为看涨。

2026-10-15看涨
《The Big 3: MRK, GILD, XOM》
AI 摘要 · MRK 正扭转一个半月的下跌趋势,并在自约 157 回落之后突破下降通道;RSI 动能转向上行,长期牛旗形态指向约 170,下月可能突破至 165-170 的新历史高点。并非必然;风险仍存;财报即将公布。

Merck是你的首选,而且今天确实跑赢了大盘。它的股价上涨了2%。他们本月底将发布财报。这里我对Merck印象深刻,因为它已经开始扭转过去一个半月左右所处的下跌趋势。看起来我们今天可能正在突破那个下行通道,听听Ben的看法会很有意思,但我认为,既然该公司已经找到了一些稳定性,现在有可能看到更高的价格走势。

Merck is your first choice and truly outperforms the market today. Its stock is up by 2%. They have an earnings announcement due at the end of this month. I am impressed with " Merck" here because it has started to reverse the downward trend it has been in for the past month and a half or so .

It looks like we may be breaking out of that down channel today, and it will be interesting to hear Ben's opinion , but I think there is a possibility of seeing higher price action now that the company has found some stability.

2026-09-09看跌
《The Big 3: ROST, MRK, AAPL》
AI 摘要 · Merck 当前的强势被视为一项负担;预计将出现下行,并通过约 100 天后到期的看跌价差为此布局。

另一只大幅上涨的是 Merc,这是你在这里三大标的中的第二个选择。他们公布了非常积极的试验消息,也许离治愈黑色素瘤,或者至少对它有一种深度治疗,又近了一步。但正在失去、维持不住动能。

它们上涨约 14%,但从那些高点回落。你怎么看 Merc?

Uh another one with a big runup is Merc, which is your second pick here in the big three. They came out with a really positive trial news. perhaps were one step closer uh to curing melanoma or having at least a profound treatment for it.

Uh but losing, you know, maintaining their momentum. They're up about 14% but falling off of those highs. How are you looking at Merc?